E for L Aim Valuation
Is EFORL-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EFORL-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EFORL-R (THB0.17) is trading above our estimate of fair value (THB0)
Significantly Below Fair Value: EFORL-R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EFORL-R?
Other financial metrics that can be useful for relative valuation.
What is EFORL-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿679.74m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.8x |
Enterprise Value/EBITDA | 15.3x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does EFORL-R's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 18.7x | ||
SMD SaintMed | 16.4x | n/a | ฿997.0m |
WINMED Winnergy Medical | 28x | n/a | ฿772.0m |
BIS Bioscience Animal Health | 20.2x | n/a | ฿1.2b |
BIZ Business Alignment | 10x | n/a | ฿2.0b |
EFORL-R E for L Aim | 57.2x | n/a | ฿679.7m |
Price-To-Earnings vs Peers: EFORL-R is expensive based on its Price-To-Earnings Ratio (57.2x) compared to the peer average (18.7x).
Price to Earnings Ratio vs Industry
How does EFORL-R's PE Ratio compare vs other companies in the TH Healthcare Industry?
Price-To-Earnings vs Industry: EFORL-R is expensive based on its Price-To-Earnings Ratio (57.2x) compared to the TH Healthcare industry average (23x).
Price to Earnings Ratio vs Fair Ratio
What is EFORL-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 57.2x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EFORL-R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.